Commentary: Molecular testing in melanoma

Journal of the American Academy of Dermatology

Volumn 70, Issue 5, 2014, Pages 863-870

  Miller, David M ^a   Flaherty, Keith T ^b   Tsao, Hensin ^b  

^a Department of Medicine   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER TEST; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; MELANOMA; MOLECULAR TESTING; NOTE; ONCOGENE RAS; PRIMARY TUMOR; PRIORITY JOURNAL; REGIONAL METASTASIS; SOMATIC MUTATION;

HUMANS; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84899079144     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.01.866     Document Type: Editorial

References (45)

1. F.W. Huang, E. Hodis, M.J. Xu, G.V. Kryukov, L. Chin, and L.A. Garraway Highly recurrent TERT promoter mutations in human melanoma Science 339 2013 957 959
2. S. Horn, A. Figl, P.S. Rachakonda, C. Fischer, A. Sucker, and A. Gast et al. TERT promoter mutations in familial and sporadic melanoma Science 339 2013 959 961
3. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
4. Nagore YH, Requena C, Traves V, Guillen C, Hayward NK, Whiteman DC, Hacker E. Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol doi:10.1016/j.jaad.2013.10.064. Published online January 6, 2014.
5. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, and D.R. Byrd et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
6. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman et al. Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
7. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
8. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, and J. Sosman et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
9. J.A. Ellerhorst, V.R. Greene, S. Ekmekcioglu, C.L. Warneke, M.M. Johnson, and C.P. Cooke et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma Clin Cancer Res 17 2011 229 235
10. L. Si, Y. Kong, X. Xu, K.T. Flaherty, X. Sheng, and C. Cui et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort Eur J Cancer 48 2012 94 100
11. G.V. Long, A.M. Menzies, A.M. Nagrial, L.E. Haydu, A.L. Hamilton, and G.J. Mann et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol 29 2011 1239 1246
12. D.Z. Chang, K.S. Panageas, I. Osman, D. Polsky, K. Busam, and P.B. Chapman Clinical significance of BRAF mutations in metastatic melanoma J Transl Med 2 2004 46
13. M. Kirschner, B. Helmke, H. Starz, A. Benner, M. Thome, and M. Deichmann Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases Melanoma Res 15 2005 427 434
14. E. Edlundh-Rose, S. Egyházi, K. Omholt, E. Månsson-Brahme, A. Platz, and J. Hansson et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing Melanoma Res 16 2006 471 478
15. L.A. Akslen, S. Angelini, O. Straume, I.M. Bachmann, A. Molven, and K. Hemminki et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival J Invest Dermatol 125 2005 312 317
16. H. Ekedahl, H. Cirenajwis, K. Harbst, A. Carneiro, K. Nielsen, and H. Olsson et al. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort Br J Dermatol 169 2013 1049 1055
17. W. Liu, J.W. Kelly, M. Trivett, W.K. Murray, J.P. Dowling, and R. Wolfe et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma J Invest Dermatol 127 2007 900 905
18. R. Kumar, S. Angelini, K. Czene, I. Sauroja, M. Hahka-Kemppinen, and S. Pyrhönen et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome Clin Cancer Res 9 2003 3362 3368
19. H. El-Osta, G. Falchook, A. Tsimberidou, D. Hong, A. Naing, and K. Kim et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes PLoS One 6 2011 e25806
20. R. Houben, J.C. Becker, A. Kappel, P. Terheyden, E.B. Bröcker, and R. Goetz et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis J Carcinog 3 2004 6
21. D. Gonzalez, L. Fearfield, P. Nathan, P. Tanière, A. Wallace, and E. Brown et al. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel Br J Dermatol 168 2013 700 707
22. A.E. Karnoub, and R.A. Weinberg Ras oncogenes: split personalities Nat Rev Mol Cell Biol 9 2008 517 531
23. S.M. Sebti Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy Cancer Cell 7 2005 297 300
24. K.T. Flaherty, F.S. Hodi, and D.E. Fisher From genes to drugs: targeted strategies for melanoma Nat Rev Cancer 12 2012 349 361
25. J.V. Heymach, D.H. Johnson, F.R. Khuri, H. Safran, L.L. Schlabach, and F. Yunus et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer Ann Oncol 15 2004 1187 1193
26. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 2006 4340 4346
27. R.D. Carvajal, C.R. Antonescu, J.D. Wolchok, P.B. Chapman, R.A. Roman, and J. Teitcher et al. KIT as a therapeutic target in metastatic melanoma JAMA 305 2011 2327 2334
28. J.R. Todd, L.L. Scurr, T.M. Becker, R.F. Kefford, and H. Rizos The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma Oncogene 33 2014 236 245
29. Y. Kong, L. Si, Y. Zhu, X. Xu, C.L. Corless, and K.T. Flaherty et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma Clin Cancer Res 17 2011 1684 1691
30. J. Guo, L. Si, Y. Kong, K.T. Flaherty, X. Xu, and Y. Zhu et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification J Clin Oncol 29 2011 2904 2909
31. F.S. Hodi, C.L. Corless, A. Giobbie-Hurder, J.A. Fletcher, M. Zhu, and A. Marino-Enriquez et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin J Clin Oncol 31 2013 3182 3190
32. D.G. Coit, R. Andtbacka, C.J. Anker, C.K. Bichakjian, W.E. Carson 3rd, and A. Daud et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines J Natl Compr Canc Netw 11 2013 395 407
33. K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression Clin Cancer Res 9 2013 6483 6488
34. M. Colombino, M. Capone, A. Lissia, A. Cossu, C. Rubino, and V. De Giorgi et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma J Clin Oncol 30 2012 2522 2529
35. M. Yancovitz, A. Litterman, J. Yoon, E. Ng, R.L. Shapiro, and R.S. Berman et al. Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma PLoS One 7 2012 e29336
36. A.H. Grossmann, K.F. Grossmann, and M.L. Wallander Molecular testing in malignant melanoma Diagn Cytopathol 40 2012 503 510
37. L. Heinzerling, S. Kühnapfel, D. Meckbach, M. Baiter, E. Kaempgen, and P. Keikavoussi et al. Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice Br J Cancer 108 2013 2164 2171
38. S. Martín-Algarra, M.T. Fernández-Figueras, J.A. López-Martín, A. Santos-Briz, A. Arance, and M.D. Lozano et al. Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology Clin Transl Oncol 2013 Oct 16 [Epub ahead of print]
39. F. Lopez-Rios, B. Angulo, B. Gomez, D. Mair, R. Martinez, and E. Conde et al. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib PLoS One 8 2013 e53733
40. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
41. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J.W. M D, and C. Garbe et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
42. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, and D.F. McDermott et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
43. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, and P. Hwu et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
44. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, and A.M. Lesokhin et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
45. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, and R. Kefford et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144